Przeszczepienie allogenicznych krwiotwórczych komórek macierzystych poprzedzone leczeniem ruksolitynibem u chorej na mielofibrozę wtórną do nadpłytkowości samoistnej, z trombofilią wrodzoną z mutacją genu protrombiny G20210A

Elżbieta Patkowska(Institute for Transfusion Medicine), Joanna Góra‐Tybor, Katarzyna Borg

Via Medica Journals

January 1, 2017

Cited by 0

Related Papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|390

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy

|Blood|2022|129

SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism

|Cell Death and Disease|2020|41

Targeting the thioredoxin system as a novel strategy against B‐cell acute lymphoblastic leukemia

|Molecular Oncology|2019|37

Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment

|Polskie Archiwum Medycyny Wewnętrznej|2022|37